Medtronic糖尿病股MiniMed Group于2025年12月19日申请美国IPO成为一家独立的公营公司。 MiniMed Group, Medtronic’s diabetes unit, filed for a U.S. IPO on December 19, 2025, to become an independent public company.

MiniMed集团(MiniMed Group)的 Medtronic糖尿病股已申请美国IPO成为一家独立的公营公司, Medtronic’s diabetes unit, MiniMed Group, has filed for a U.S. IPO to become an independent public company, aiming to list on Nasdaq under the ticker "MMED." 2025年12月19日宣布的备案标志着Medtronic计划摆脱糖尿病事业的关键一步,该计划的收益是偿还公司间债务和满足公司一般需要。 The filing, announced on December 19, 2025, marks a key step in Medtronic’s plan to spin off its diabetes business, with proceeds to repay intercompany debt and fund general corporate needs. MiniMed报告说,在截至2024年10月24日的六个月期间,销售额为14.8亿美元,净损失为2 100万美元,比上一年损失2 300万美元有所改进。 MiniMed reported a $21 million net loss on $1.48 billion in sales for the six months ending October 24, 2024, improving from a $23 million loss the prior year. 预计由主要承销商领导的IPO将在18个月内完成,Medtronic将保留至少80.1%的投票权股. The IPO, led by major underwriters, is expected to finalize within 18 months, with Medtronic retaining at least 80.1% of voting shares. 这一举动反映了公司分离的广泛趋势,以及恢复了IPO市场,美国在2025年募集753亿美元。 The move reflects a broader trend of corporate separations and a revived IPO market, with U.S. offerings raising $75.3 billion in 2025.